Yong-yu Yang
Shanghai, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages.
Journal: Hepatology (Baltimore, Md.)
Published: June 25, 2025
Proliferation, migration, and differentiation of circulating ILC precursors in HBV infection-associated fibrosis.
Journal: European journal of medical research
Published: May 26, 2025
Suppressing MASH fibrotic progression by blocking succinate-GPR91 signaling in HSCs.
Journal: Hepatology (Baltimore, Md.)
Published: December 18, 2024
New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024.
Journal: Acta pharmacologica Sinica
Published: September 14, 2024
Both liver parenchymal and non-parenchymal cells express JCAD protein under various circumstances.
Journal: Clinical and molecular hepatology
Published: March 19, 2024
JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis.
Journal: Clinical and molecular hepatology
Published: November 29, 2023
JCAD deficiency delayed liver regenerative repair through the Hippo-YAP signalling pathway.
Journal: Clinical and translational medicine
Published: November 21, 2023
Secretome of senescent hepatic stellate cells favors malignant transformation from nonalcoholic steatohepatitis-fibrotic progression to hepatocellular carcinoma.
Journal: Theranostics
Published: April 17, 2023
Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis.
Journal: Acta pharmacologica Sinica
Published: October 02, 2021
Showing 1-10 of 10
Last Updated: 09/26/2026